LINC02119: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02119

NCBI ID: G101929745

LINC02119

Other Name(s): long intergenic non-protein coding RNA 2119 | Long intergenic non-protein coding RNA 2119

LINC02119: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02119 is a long non-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located within the last exon of the HASN gene, which encodes a protein involved in the detoxification of xenobiotics. The encoded protein has been shown to have both antioxidant and pro-inflammatory effects. The presence of LINC02119 in the HASN gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

The drug targeting potential of LINC02119 is based on its expression and effects on the HASN gene. The encoded protein has been shown to have both antioxidant and pro-inflammatory effects. The antioxidant effects of HASN protein include its ability to neutralize free radicals and reduce oxidative stress. The pro-inflammatory effects of HASN protein include its ability to activate immune cells and contribute to the development of autoimmune disorders.

The potential drug targets for LINC02119 are based on its expression and its effects on the HASN gene. One of the potential drug targets is the inhibition of HASN protein, which could lead to the reduction of the pro-inflammatory effects of the protein and potentially treat autoimmune disorders. Another potential drug target is the stimulation of HASN protein, which could lead to the increase of the antioxidant effects of the protein and potentially treat cancer and neurodegenerative diseases.

Biomarker Potential

The biomarker potential of LINC02119 is based on its expression and its effects on the HASN gene. The encoded protein has been shown to have both antioxidant and pro-inflammatory effects. The antioxidant effects of HASN protein have been shown to be associated with a reduced risk of certain diseases, including cancer and neurodegenerative diseases. The pro-inflammatory effects of HASN protein have been shown to contribute to the development of autoimmune disorders.

The potential biomarkers for LINC02119 are based on its expression and its effects on the HASN gene. One of the potential biomarkers is the level of HASN protein expression, which could be used as a measure of the activity of the encoded gene. Another potential biomarker is the level of antioxidant activity of HASN protein, which could be used as a measure of the effectiveness of the encoded gene in reducing oxidative stress.

Conclusion

In conclusion, LINC02119 is a long non-coding RNA that has been identified as a potential drug target and biomarker. Its expression and effects on the HASN gene make it a promising candidate for drug targeting and biomarker development. Further research is needed to fully understand the potential drug targeting and biomarker potential of LINC02119.

Protein Name: Long Intergenic Non-protein Coding RNA 2119

The "LINC02119 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02119 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets